Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

WCLC 2022 | Developments in immunotherapy for lung cancer

Hossein Borghaei • 7 Aug 2022
WCLC 2022
Lung Cancer

Hossein Borghaei, DO, MS, Fox Chase Cancer Center, Philadelphia, PA, talks on advances in immunotherapy for lung cancer. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.

More from Hossein Borghaei

3:02
Should patients with lung cancer continue IO after completing 2 years of IO?
Hossein Borghaei • 28 Feb 2023
2:29
Immunotherapy clinical trials for mesothelioma to look out for
Hossein Borghaei • 28 Feb 2023
3:24
Novel immunotherapy agents on the horizon for lung cancer
Hossein Borghaei • 28 Feb 2023
2:21
EA5163/S1709/INSIGNA: the timing of pembrolizumab +/- chemo as 1L treatment and maintenance in NSCLC
Hossein Borghaei • 28 Feb 2023

Related Videos

1:03
The benefits of liquid biopsies for lung cancer in the community setting
Deepti Behl • 9 Apr 2024
0:57
STK-012-101: STK-012 in advanced solid tumors
Alexander Spira • 15 Mar 2024
3:34
FLAURA2: EGFRm dynamics in NSCLC treated with osimertinib
Pasi Jänne • 8 Apr 2024
0:54
FURVENT: furmonertinib in EGFR exon 20 mutant NSCLC
Alexander Spira • 15 Mar 2024
The content of VJOncology is intended for healthcare professionals